
Magnesium for night leg cramps: a 2026 trial reinforces the negative evidence
A 2026 randomized trial found magnesium no better than placebo for recurrent leg cramps, consistent with an earlier Cochrane review.
For typical night leg cramps in older adults, magnesium has not produced a clinically meaningful benefit over placebo and can cause gastrointestinal effects.
What the 2026 trial tested
A randomized three-arm trial published in 2026 enrolled 121 adults aged 50 to 85 who had experienced at least two leg cramps per week. Participants used knee-high compression stockings, magnesium hydrochloride or placebo pills. The primary outcome was change in weekly cramp frequency, with nocturnal awakenings and pain also assessed.
The study is relevant because magnesium is a common self-treatment for night cramps despite longstanding uncertainty. It tested recurrent cramps in older adults, not pregnancy-related cramps, exercise-associated cramping or symptoms caused by a specific disease. Those populations should not be merged.

Magnesium did not beat placebo
At follow-up, the magnesium and placebo groups both had a median of three cramps per week. The baseline-adjusted mean difference was small and not statistically significant. Compression stockings, by contrast, reduced cramp frequency and related outcomes versus placebo, although some participants stopped using them because of adverse reactions.
Improvement in the magnesium group from baseline would have looked encouraging without the placebo comparison. The randomized result shows that natural fluctuation, expectation and study participation can account for apparent change. The between-group estimate is the relevant test of added benefit.
The result agrees with the earlier evidence synthesis
A 2020 Cochrane review included five placebo-controlled trials in adults with typical idiopathic rest cramps. Magnesium produced little or no difference in cramp frequency, intensity or duration, and the reviewers concluded that clinically meaningful prevention was unlikely in older adults.
The review found conflicting, lower-quality evidence for pregnancy-associated cramps and no randomized trials for exercise-associated cramps. Marketing often ignores those boundaries by treating every cramp as evidence of magnesium deficiency. A symptom label is not a diagnosis.
Deficiency and supplementation are different questions
Magnesium deficiency can cause neuromuscular symptoms and warrants evaluation when clinically suspected. That does not mean most people with nocturnal cramps are deficient or will benefit from extra magnesium. Medicines, hydration, nerve or vascular problems and other factors may be relevant depending on the individual.
The NIH Office of Dietary Supplements notes that supplemental magnesium commonly causes diarrhea, nausea and abdominal cramping. Very high intake can cause serious toxicity, particularly when kidney function is impaired. Magnesium also interacts with bisphosphonates and some antibiotics.

How the new evidence should guide decisions
The 2026 trial strengthens an already negative answer for routine magnesium in older adults with idiopathic night cramps. It does not rule out treating a documented deficiency or answer every special population. The product form and amount also cannot rescue a claim that lacks condition-specific evidence.
People with frequent, severe or new cramps should seek an assessment rather than escalating supplements. A clinician can review medicines and possible underlying causes. When magnesium is used for another indication, total supplemental intake and timing around interacting drugs still matter. The news is straightforward: another controlled trial did not show the expected cramp benefit.
Cramp marketing often confuses mechanism with diagnosis
Magnesium participates in nerve and muscle function, so it is easy to frame any cramp as a sign of inadequate magnesium. That is a mechanistic shortcut. A nutrient can be essential while supplementation fails in people who are already sufficient. The randomized evidence in typical older adults is more relevant than the general statement that muscles require magnesium.
Labels may also combine magnesium with potassium, calcium or herbs, making both benefit and adverse effects difficult to attribute. Electrolytes should not be added indiscriminately because kidney function and medicines influence their handling. A targeted evaluation is more appropriate when cramps follow a new drug, accompany weakness or swelling, occur during exertion, or change suddenly in pattern. Future cramp trials should verify baseline magnesium status and separate nocturnal cramps from restless legs or neuropathic symptoms. They should report sleep disruption as well as frequency, because the outcome that matters most may be the ability to sleep rather than a small numerical change in episodes.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.